NEW YORK, March 19, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Zimmer Holdings, Inc. (NYSE: ZMH), Covidien plc (NYSE: COV), Laboratory Corporation of America Holdings (NYSE: LH), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Amgen, Inc. Analyst Notes
On March 14, 2014, Amgen, Inc. (Amgen) announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma. The findings showed that talimogene laherparepvec has reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the body. The Company reported that the analysis recorded tumor-level responses from a pivotal Phase 3 study evaluating talimogene laherparepvec in patients with injectable unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). "These data add to the body of evidence supporting talimogene laherparepvec's local and distant effect, and its potential ability to stimulate a systemic anti-tumor immune response," said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen. "Melanoma remains a devastating and difficult-to-treat disease, and talimogene laherparepvec continues to demonstrate encouraging results in this setting." The full analyst notes on Amgen, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03192014/AMGN/report.pdf
Zimmer Holdings, Inc. Analyst Notes
On March 5, 2014, Zimmer Holdings, Inc. (Zimmer) announced that its Board of Directors has approved an increased quarterly cash dividend for Q1 FY 2014. The increased dividend of $0.22 per share represents a 10% increase over its Q1 FY 2013 dividend. The Company informed that the dividend is payable on April 25, 2014, to stockholders of record as of the close of business on March 28, 2014. The full analyst notes on Zimmer Holdings, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03192014/ZMH/report.pdf
Covidien plc Analyst Notes
On March 14, 2014, Covidien plc (Covidien) announced that it intends to release its Q2 FY2014 results on April 25, 2014. The results will be followed by a conference call for investor, scheduled to be held at 8:30 a.m. ET on the same day. The call will be accessible throughCovidien's website or by telephone.Also, an audio replay of the conference call will be available beginning at 11:30 a.m. ET on April 25, 2014 through 5:00 p.m. ET on May 2, 2014.The full analyst notes on Covidien plc are available to download free of charge at:
http://www.AnalystsReview.com/03192014/COV/report.pdf
Laboratory Corporation of America Holdings Analyst Notes
On March 11, 2014, Laboratory Corporation of America Holdings (LabCorp) announced that its Zero Coupon Convertible Subordinated Notes due 2021 will accrue contingent cash interest for the period of March 12, 2014 to September 11, 2014, at a rate of no less than 0.125% of the average market price of Zero Coupon Note for the five trading days ended March 6, 2014. The Company informed that it has determined the contingent cash interest to be approximately $1.56 per Note, and is payable to holders of the Zero Coupon Notes as of the record date of August 27, 2014. LabCorp expects the payment of the contingent cash interest to take place on September 11, 2014. The full analyst notes on Laboratory Corporation of America Holdings are available to download free of charge at:
http://www.AnalystsReview.com/03192014/LH/report.pdf
Enanta Pharmaceuticals, Inc. Analyst Notes
On March 4, 2014, Enanta Pharmaceuticals, Inc. (Enanta) announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. The data presented showed that ABT-493 has a substantially improved in vitro profile compared to earlier generation HCV NS3/4A protease inhibitors and displays potent and broad genotypic activity in genotypes 1a, 1b, 2a, 3a, 4a, and 6a, against which many other HCV NS3/4A protease inhibitors have significantly lower potency. Further, Enanta stated that in vitro ABT-492 retains potency against most of the clinically important resistance-associated variants in genotype 1 and is fully active against variants resistant to NS5A or NS5B inhibitors. The full analyst notes Enanta Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03192014/ENTA/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
